On the unique binding and activating properties of xanomeline at the M1 muscarinic acetylcholine receptor

Molecular Pharmacology

Volumn 53, Issue 6, 1998, Pages 1120-1130

  Christopoulos, Arthur ^a   Pierce, Tracie L ^a   Sorman, Jennifer L ^a   El Fakahany, Esam E ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATROPINE; CARBACHOL; CHOLINERGIC RECEPTOR; MUSCARINIC M1 RECEPTOR; PIRENZEPINE; XANOMELINE;

ALZHEIMER DISEASE; ANIMAL CELL; ARTICLE; CHO CELL; CONTROLLED STUDY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY;

ANIMALS; ATROPINE; CARBACHOL; CHO CELLS; CRICETINAE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MUSCARINIC AGONISTS; N-METHYLSCOPOLAMINE; NITRIC OXIDE SYNTHASE; PHOSPHATIDYLINOSITOLS; PYRIDINES; RECEPTOR, MUSCARINIC M1; RECEPTORS, MUSCARINIC; THIADIAZOLES; TIME FACTORS;

EID: 0031866950     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Arunlakshana O and Schild HO (1959) Some quantitative uses of drug antagonists. Br J Pharmacol 14:48-58.
2. Bodick NC, Offen WW, Levey AI, Cutler NC, Gauthier SG, Satlin A, Shannon HE, Tollefson GD, Rasmussen K, Bymaster FP, Hurley DJ, Potter WZ, and Paul SM (1997) Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioural symptoms in Alzheimer's disease. Arch Neurol 54:465-473.
3. Bradford M (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Annal Biochem 72:248-254.
4. Bredt DS and Snyder SH (1989) Nitric oxide mediates glutamate-linked enhancement of cGMP levels in the cerebellum. Proc Natl Acad Sci USA 86:9030-9033.
5. Bymaster FP, Whitesitt CA, Shannon HE, DeLapp N, Ward JS, Calligaro DO, Shipley LA, Buelke-Sam JL, Bodick NC, Farde L, Sheardown MJ, Olesen PH, Hansen KT, Suzdak PD, Swedberg MDB, Sauerberg P, and Mitch CH (1997) Xanomeline: a selective muscarinic agonist for the treatment of Alzheimer's disease. Drug Dev Res 40:158-170.
6. 1 receptors by xanomeline. Eur J Pharmacol 334:R3-R4.
7. 2-adrenergic receptor stimulation of adenylyl cyclase by salmeterol: evidence for a quasi-irreversible binding to an exosite. Mol Pharmacol 49:182-189.
8. Coleman RA, Johnson M, Nials AT, and Vardey CJ (1996) Exosites: their current status, and their relevance to the duration of action of long-acting β2-adrenoceptor agonists. Trends Pharmacol Sci 17:324-330.
9. Ferrari-Dileo G, Mash DC, and Flynn, DD (1995) Attenuation of muscarinic receptor-G-protein interaction in Alzheimer disease. Mol Chem Neuropathol 24:69-91.
10. Giacobini E (1992) Cholinomimetic replacement of cholinergic function in Alzheimer's disease, in Treatment of Dementias (Meyer EM, Simpkins JW, Yamamoto J, and Crews FT, eds) pp 19-34, Plenum Press, NY.
11. 2-adrenergic receptor. J Biol Chem 271:24029-24035.
12. Hu J, Wang SZ, and El-Fakahany EE (1991) Effects of agonist efficacy on desensitization of phosphoinositide hydrolysis mediated by m1 and m3 muscarinic receptors expressed in Chinese hamster ovary cells J Pharmacol Exp Ther 257:938-945.
13. 2-Adrenergic receptor desensitization, internalization, and phosphorylation in response to full and partial agonists. J Biol Chem 272:23871-23879.
14. Kenakin TP (1997) Pharmacologic Analysis of Drug-Receptor Interaction, 3rd ed, Lippincott-Raven, New York.
15. Kostenis E and Mohr K (1996) Two-point kinetic experiments to quantify allosteric effects on radioligand dissociation. Trends Pharmacol Sci 17:280-283.
16. 1 muscarinic receptor-G protein coupling in Alzheimer's disease. J Neuropathol Exp Neurol 54:783-789.
17. Lazareno S and Birdsall NJM (1995) Detection, quantitation, and verification of allosteric interactions of agents with labeled and unlabeled ligands at G protein-coupled receptors: interactions of strychnine and acetyicholine at muscarinic receptors. Mol Pharmacol 48:362-378.
18. Lee NH and El-Fakahany EE (1991) Allosteric antagonists of the muscarinic acetylcholine receptor. Biochem Pharmacol 42:199-205.
19. Leff P, Prentice DJ, Giles H, Martin GR, and Wood J (1990) Estimation of agonist affinity and efficacy by direct, operational model fitting. J Pharmacol Methods 23:225-237.
20. Lohse MJ (1993) Molecular mechanisms of membrane receptor desensitization. Biochim Biophys Acta 1179:171-188.
21. Mash DC, Flynn DD, and Potter LT (1985) Loss of M2 muscarine receptors in the cerebral cortex in Alzheimer's disease and experimental cholinergic denervation. Science (Washington D C) 228:1115-1117.
22. Nathanson NM (1989) Regulation and development of muscarinic receptor number and function, in The Muscarinic Receptors (Brown JH, ed) pp 419-454, Humana Press, NJ.
23. 2-adrenoceptor agonist, salmeterol. Br J Pharmacol 108:507-515.
24. Proška J and Tucek S (1994) Mechanisms of steric and cooperative actions of alcuronium on cardiac muscarinic receptors. Mol Pharmacol 45:709-717.
25. Quirion R, Aubert I, Lapchak PA, Schaum RP, Teolis S, Gauthier S, and Araujo DM (1989) Muscarinic receptor subtypes in human neurodegenerative disorders: focus on Alzheimer's disease. Trends Pharmacol Sci 10(suppl.):80-84.
26. 1 receptors. J Pharmacol Exp Ther 269:271-281.
27. Wang SZ, Zhu SZ, and El-Fakahany EE (1994) Efficient coupling of m5 muscarinic acetyicholine receptors to activation of nitric oxide synthase. J Pharmacol Exp Ther 268:552-557.
28. Zhu SZ, Wang SZ, Hu J, and El-Fakahany EE (1994) An arginine residue conserved in most G protein-coupled receptors is essential for the function of the m1 muscarinic receptor. Mol Pharmacol 45:517-523.